Ramosetron (Iribo)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 15:14, 9 September 2016 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== Serotonin 5HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties. ==History of FDA approval== Not FDA-approved; avail...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

Serotonin 5HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties.

History of FDA approval

Not FDA-approved; available in Japan and Southeast Asia.

Also known as

IBset, Nasea, Nozia

Retrieved from "https://hemonc.org/w/index.php?title=Ramosetron_(Iribo)&oldid=11634"